Q32 Bio Inc., incorporated in 2015 under the laws of the State of Delaware, is a genetic medicine company dedicated to improving the lives of patients with rare genetic diseases and addressing significant unmet medical needs by treating the underlying causes of the disease. The Company's proprietary platform is designed to utilize adeno-associated virus vectors, or AAVHSCs, derived from human hematopoietic stem cells to accurately and efficiently deliver in vivo genetic medicines in a wide range of genetic diseases through gene therapy or nuclease gene editing. The unique properties of its 15 new AAVHSC proprietary kits enable it to focus on gene editing methods called gene correction, either by replacing entire disease genes in the genome with complete functional copies or precisely repairing individual mutated nucleotides by utilizing homologous recombination of naturally occurring DNA repair processes or HR.